Stay updated with breaking news from Asher Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jazz Pharmaceuticals is licensing rights to a Werewolf Therapeutics cytokine therapy that’s on track to reach clinical testing next year. The deal gives Jazz a drug candidate that expands the company’s scope to immuno-oncology.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appointment of Ian T. Clark to its Board of Directors. Mr. Clark most recently served as Chief Executive Offi...
/PRNewswire/ -- The "Targeted Immunotherapy in Oncology" report has been added to ResearchAndMarkets.com's offering. This research service investigates...
The field of biotechs pursuing new interleukin-2 cancer immunotherapies is filled with companies engineering different versions of that signaling protein. Avenge Bio CEO Mike Heffernan said his startup stands apart with a cell therapy that produces human IL-2 that could offer advantages compared to engineered versions of that protein.
MedCity News Biotech IPO wave rolls on as Werewolf, Vaccitech raise $230M for clinical trials Vaccitech and Werewolf Therapeutics joined the public markets, raising a combined $230 million. The vaccine developer and the cancer immunotherapy biotech will apply the IPO proceeds toward clinical development of their respective pipelines. Shares0 Two more biotech companies are joining the public markets. Werewolf Therapeutics and Vaccitech priced their respective IPOs late Thursday, raising a combined $230 million for multiple clinical trials. Werewolf was able to boost the size of its deal, ...